CONMED Business Summary

CONMED Corporation (CNMD) is a global medical technology firm that generates revenue primarily through the direct sale and distribution of specialized surgical devices and equipment. The company operates through two core business segments: Orthopedic Surgery, which provides sports medicine implants, powered instruments, and allograft tissues; and General Surgery, which focuses on endo-mechanical instrumentation, electrosurgical generators, and advanced smoke evacuation systems. As of early 2026, CONMED has strategically exited its gastroenterology product lines to concentrate resources on high-margin, high-growth platforms including the AirSeal insufflation system, Buffalo Filter smoke evacuation technology, and the BioBrace soft-tissue scaffold. In the competitive landscape, CONMED positions itself as a differentiated niche leader against larger diversified peers such as Stryker, Medtronic, and Smith & Nephew, leveraging its specialized focus on minimally invasive procedural efficiency to capture market share in ambulatory surgery centers and robotic-assisted surgery environments. Originally founded in 1970 by Eugene Corasanti, CONMED is currently led by President and CEO Patrick Beyer, who assumed the role in January 2025 following a successful tenure as the company’s Chief Operating Officer and former CEO of ICNet. The executive team includes Executive VP and CFO Todd Garner, a veteran finance leader with a pedigree from C.R. Bard, and Andrew Moller, who joined as VP and Corporate Controller in 2025 from Smith & Nephew. The company’s governance is overseen by Board Chair LaVerne Council, former CIO of Johnson & Johnson, and includes notable directors such as Mark Kaye, the CFO of Elevance Health. CONMED maintains a strong institutional investor base, with major holdings by BlackRock, Vanguard Group, and Earnest Partners, reflecting confidence in the firm’s transition toward a high-growth, specialized surgical portfolio.